# Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

> **NCT00710580** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 350 (actual)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** ABT-874
- **BIOLOGICAL:** etanercept
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00710580
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2013-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710580, "Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00710580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*